The COMPEL study provides the first formal data supporting the common practice of continuing osimertinib when adding chemotherapy after disease progression. This is a significant finding as previous studies with older-generation TKIs showed this strategy was not helpful, highlighting osimertinib's unique CNS-protective benefits.

The COMPEL study showed a near doubling of progression-free survival by continuing osimertinib with chemotherapy after first-line progression. This contradicts findings with first-generation TKIs (like gefitinib) and establishes "TKI continuation" as a new standard of care.

The LAURA trial shows a favorable overall survival trend for osimertinib consolidation even though 80% of placebo patients received osimertinib upon progression. This high crossover rate makes the persistent trend highly significant, suggesting a strong benefit to earlier TKI administration.

Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.

When EGFR+ NSCLC transforms to small cell, clinicians often continue the TKI osimertinib alongside chemotherapy. This practice is largely based on expert consensus and the rationale of suppressing any remaining EGFR-driven clones, rather than on definitive clinical trial data showing a clear benefit.

For patients with otherwise well-controlled disease who develop isolated oligoprogression in the brain, evidence suggests a better survival outcome from adding local therapy (like SRS) and continuing the current effective systemic therapy, rather than switching the systemic regimen entirely.

For EGFR-mutated NSCLC patients with brain metastases, even numerous ones (>30), potent systemic therapy like osimertinib plus chemotherapy is often initiated first. This can achieve high rates of complete intracranial response, allowing clinicians to delay or entirely avoid whole-brain radiation and its long-term toxicities.

While blinatumomab-TKI combinations avoid systemic chemotherapy toxicity, they are associated with higher rates of central nervous system (CNS) relapses. This necessitates an increased number of intrathecal chemotherapy doses to prevent CNS disease, a critical nuance for managing this 'simpler' approach.

While research pursues mechanism-based strategies (e.g., 4th-gen TKIs) for acquired resistance, recent practical breakthroughs are mechanism-agnostic, like ADCs or chemotherapy combinations. This highlights a pragmatic, broad-spectrum approach to treating progression after frontline osimertinib.